3 ms·
> The dogmatic preference for experienced CEOs in biotech is a relatively recent phenomenon (last 15-20 years). I guess it's relative, I'm not even 30 :) FWIW
by boltzmannbrain 7y ago
> The dogmatic preference for experienced CEOs in biotech is a relatively recent phenomenon (last 15-20 years).
I guess it's relative, I'm not even 30 :)
FWIW the pushback I get from big pharma is less around age but rather as an AI guy saying "look I solved that thing you've spent 20 years working on."
- aaavl2821 7y agoYeah that's fair, from ppl I know at AI drug discovery companies it seems like selling to big pharma is tough. Potentially bc the people who assess the technical feasibility of your product may be put out of a job by it :/ Have you tried selling to startups? From what I've heard they are better customers for AI drug discovery services as there is less entrenched interest in manual med chem and they value lower cost / fast iteration more
- boltzmannbrain 7y agoAI drug discovery is not an ideal market -- crowded, and long horizons to validation checkpoints. Our value prop to pharma is in clinical trials utilities. Relative to drug discovery, better path from pilots to revenue deals, but still cumbersome. Nonetheless your advice to target startups is sound :)